Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07069894
Starting soon Observational

Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）

NCT07069894 · tracked via the Priya Life Science China tracker
Sponsor
Southeast University, China
Phase
Observational
Started
2025-08-01
Last updated
2025-07-17

Condition(s) studied

Sepsis

Study summary

Xuebijing injection (XBJ) showed proven efficacy in the EXIT-SEP trial (NCT03238742), lowering 28-day mortality. However, its real-world effectiveness requires validation due to the trial's strict criteria. Broader clinical evaluation is imperative.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Hospitalized patients aged ≥18 years * Sepsis diagnosis meeting Sepsis-3 criteria * Informed consent signed by patient or legally authorized representative Exclusion Criteria: * Patients with a prior history of sepsis * Sepsis diagnosis \>48 hours prior to enrollment * Current participation in clinical trial

Primary outcome measure(s)

  • 28-day all-cause mortality — 28 days after enrollment

Trial sites (1)

FacilityCityRegionStatus
Zhongda hospital, Southeast University Nanjing Jiangsu

More Southeast University, China trials in China

Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients Recruiting
Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS Starting soon
Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS Recruiting
OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury Recruiting
Effect of EIT-guided PEEP in ARDS Patients Recruiting

Other trials for the same condition

Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock Recruiting
AN69ST Verse PS in CBP in Septic Children Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients Recruiting
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients Recruiting
Early Sepsis Recognition Tool Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07069894 on ClinicalTrials.gov ↗ ← All trials in China